Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for ...

I took part in a 2012 psilocybin trial. What I’m seeing now horrifies me,” writes Erica Rex, author of the new book “Seeing ...

The right counselor can make a huge difference.

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...

Carefully supervised therapy sessions with psychedelic drugs can help alleviate depression, anxiety and addiction, studies ...

Psilocybin, the active compound in hallucinogenic mushrooms, is edging into mainstream psychiatry in parts of Europe – with Switzerland already treating patients and the Czech Republic opening tightly ...